Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (Eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP), and for Xyzal (Levocetirizine dihydrochloride), a new anti-histamine to be made available in Japan for eight years.
Subscribe to our email newsletter
Revolade is an oral treatment that stimulates the production of blood platelets, which are essential to normal clotting.
GSK claimed that the anti-allergic drug, Xyzal, has been approved for the treatment of allergic rhinitis, urticaria, eczema and dermatitis, prurigo and cutaneous pruritus in patients over the age of seven years.
GSK Japan president Philippe Fauchet said that the approvals were very important to the company as they demonstrate the progress they are making in gaining approvals in Japan.